clinical trial · NCT03547973
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Gilead Sciences·phase2·recruiting·n = 827
Metastatic Urothelial CancerSacituzumab Govitecan-hziyPembrolizumabCisplatinAvelumabZimberelimabCarboplatinGemcitabineDomvanalimab
brief summary
The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).
started
Aug 13, 2018
primary completion
Apr 1, 2030
completion
Apr 1, 2030
last updated
Mar 16, 2026
detailed description
Non-Randomized for Cohorts 1,2,3, and 4; Randomized for Cohorts 5, 6, and 7. Cohort 5 has been cancelled, effective December 2023.
official title
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol